Skip to main content

Relugolix Disease Interactions

There are 2 disease interactions with relugolix.

Major

Relugolix (applies to relugolix) osteoporosis

Major Potential Hazard, Moderate plausibility.

Relugolix is contraindicated for use in women with known osteoporosis because of the risk of further bone loss. Prior to initiating therapy, an assessment of bone mineral density by dual-energy X-ray absorptiometry (DXA) is recommended. Carefully consider the risks of treatment in women with a history of a low trauma fracture or risk factors for osteoporosis. Treatment should be limited to 24 months due to risk of continued bone loss which may not be reversible.

References

  1. (2023) "Product Information. Myfembree (estradiol/norethindrone/relugolix)." Myovant Sciences, Inc.
Moderate

GNRH antagonists (applies to relugolix) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Electrolyte Abnormalities, Long QT Syndrome

Androgen deprivation therapy may prolong the QT/QTc interval. Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval. Consider periodic monitoring of EKG and electrolytes.

References

  1. (2013) "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc
  2. (2021) "Product Information. Orgovyx (relugolix)." Myovant Sciences, Inc.

Relugolix drug interactions

There are 350 drug interactions with relugolix.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer